Lineage Cell Therapeutics (LCTX) Common Equity (2010 - 2026)

Lineage Cell Therapeutics has reported Common Equity for 17 years, with the latest figure at $52.7 million in Q1 2026.

• For the quarter ending Q1 2026, Common Equity fell 32.14% year-over-year to $52.7 million; the trailing twelve-month figure through Mar 2026 stood at $52.7 million (down 32.14% YoY), and the FY2025 full-year result was $44.5 million, down 42.15% from the prior year.
• Common Equity for Q1 2026 stood at $52.7 million, up from $44.5 million in the prior quarter.
• The five-year high for Common Equity was $85.2 million in Q1 2022, with the low at $20.8 million in Q3 2025.
• Historically, Common Equity has averaged $65.2 million across 5 years, with a median of $69.0 million in 2023.
• Annual changes were most pronounced in 2024 — Common Equity rose 24.17% — and 2025, when it plunged 67.9%.
• Lineage Cell Therapeutics' Common Equity stood at $71.9 million in 2022, then fell by 13.78% to $62.0 million in 2023, then climbed by 24.17% to $77.0 million in 2024, then sank by 42.15% to $44.5 million in 2025, then grew by 18.29% to $52.7 million in 2026.
• The last three Common Equity figures came in at $52.7 million (Q1 2026), $44.5 million (Q4 2025), and $20.8 million (Q3 2025), per Business Quant data.